Ginkgo Bioworks Holdings Inc. (NYSE:DNA) finished Thursday with an addition of $0.08 to close at $2.95, an upside of 2.79 percent. An average of 25,472,701 shares of common stock have been traded in the last five days. There was a fall of -$0.18 in the past week, and it reached a new high 7 times over the past 12 months. The last 20 days have seen an average of 21,621,006 shares traded, while the 50-day average volume stands at 25,280,209.
DNA stock has increased by 9.67% in the last month. The company shares reached their 1-month lowest point of $2.35 on 09/06/22. With the stock rallying to its 52-week high on 01/03/22, shares of the company touched a low of $2.09 and a high of $15.86 in 52 weeks. It has reached a new high 1 time so far this year and lost -64.50% or -$5.36 in price. In spite of this, the price is down -81.40% from the 52-week high.
China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal
Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.
Simply click here and the name & trading symbol are yours.
Ginkgo Bioworks Holdings Inc. (DNA) has a trailing price-to-sales (P/S) ratio at 9.09, the price-to-book (PB) ratio at 3.11.
The quick ratio of Ginkgo Bioworks Holdings Inc. for the three months ended June 29 was 11.80, and the current ratio was 11.80, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.03 and a total debt to equity ratio of 0.03 for the quarter ending June 29. Its gross profit as reported stood at $184.15 million compared to revenue of $313.84 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Ginkgo Bioworks Holdings Inc.’s return on assets was -143.20%.
The analyst consensus anticipated Ginkgo Bioworks Holdings Inc.’s latest quarter earnings to come in at -$0.04 per share, but it turned out to be -$0.41, a -925.00% surprise. For the quarter, EBITDA amounted to -$637.3 million. Shareholders own equity worth $1.5 billion.
From a technical analysis perspective, let’s take a brief look at Ginkgo Bioworks Holdings Inc. (DNA) price momentum. RSI 9-day as of the close on 22 September was 50.89%, suggesting the stock is Neutral, with historical volatility in this time frame at 67.27%.
As of today, DNA’s price is $2.96 -5.75% or -$0.18 from its 5-day moving average. DNA is currently trading +3.87% higher than its 20-day SMA and +1.72% higher than its 100-day SMA. However, the stock’s current price level is -7.52% below the SMA50 and -69.71% below the SMA200.
The stochastic %K and %D were 54.29% and 58.10%, respectively, and the average true range (ATR) was 0.26. With the 14-day stochastic at 57.14% and the average true range at 0.27, the RSI (14) stands at 50.55%. The stock has reached -0.10 on the 9-day MACD Oscillator while the 14-day reading was at 0.02.
BofA Securities downgraded Ginkgo Bioworks Holdings Inc. (NYSE: DNA) to a an Underperform rating in its most recent analyst report. Previously, the stock was rated as a Neutral.